314 related articles for article (PubMed ID: 24286249)
1. Factor VIII assay mimicking in vivo coagulation conditions.
Kusch M; Grundmann C; Keitel S; König H
Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
3. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
Gilmore R; Harmon S; Gannon C; Byrne M; O'Donnell JS; Jenkins PV
Haemophilia; 2010 Jul; 16(4):671-4. PubMed ID: 20148980
[TBL] [Abstract][Full Text] [Related]
4. One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ; Damgaard M; Hillarp A
Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
[TBL] [Abstract][Full Text] [Related]
5. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
Salvagno GL; Astermark J; Lippi G; Ekman M; Franchini M; Guidi GC; Berntorp E
Haemophilia; 2009 Jan; 15(1):290-6. PubMed ID: 19149855
[TBL] [Abstract][Full Text] [Related]
6. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays.
Pavlova A; Delev D; Pezeshkpoor B; Müller J; Oldenburg J
Thromb Haemost; 2014 May; 111(5):851-61. PubMed ID: 24452774
[TBL] [Abstract][Full Text] [Related]
7. Plasmatic tissue factor pathway inhibitor is a major determinant of clotting in factor VIII inhibited plasma or blood.
Knappe S; Gorczyca ME; Jilma B; Derhaschnig U; Hartmann R; Palige M; Scheiflinger F; Dockal M
Thromb Haemost; 2013 Mar; 109(3):450-7. PubMed ID: 23348798
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
9. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
10. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
[TBL] [Abstract][Full Text] [Related]
11. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
Bassus S; Wegert W; Krause M; Escuriola-Ettinghausen C; Siegemund A; Petros S; Scholz T; Scharrer I; Kreuz W; Engelmann L; Kirchmaier CM
Platelets; 2006 Sep; 17(6):378-84. PubMed ID: 16973498
[TBL] [Abstract][Full Text] [Related]
12. Assay discrepancy in mild haemophilia A.
Armstrong E; Hillarp A
Eur J Haematol Suppl; 2014 Aug; 76():48-50. PubMed ID: 24957107
[TBL] [Abstract][Full Text] [Related]
13. A bispecific antibody demonstrates limited measurability in routine coagulation assays.
Hartmann R; Feenstra T; Knappe S; Schrenk G; Scheiflinger F; Dockal M
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):353-365. PubMed ID: 32467424
[TBL] [Abstract][Full Text] [Related]
14. Performance evaluation of Revohem
Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
[TBL] [Abstract][Full Text] [Related]
15. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype.
Cid AR; Calabuig M; Cortina V; Casaña P; Haya S; Moret A; Cabrera N; Aznar JA
Haemophilia; 2008 Sep; 14(5):1049-54. PubMed ID: 18540892
[TBL] [Abstract][Full Text] [Related]
16. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Lundblad RL; Kingdon HS; Mann KG; White GC
Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
[TBL] [Abstract][Full Text] [Related]
17. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
[TBL] [Abstract][Full Text] [Related]
18. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
19. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
20. Potency estimation of recombinant factor VIII: effect of assay method and standard.
Hubbard AR; Bevan SA; Weller LJ
Br J Haematol; 2001 May; 113(2):533-6. PubMed ID: 11380427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
